Aptinyx stock soars on premarket leading volume after positive trial results of PTSD treatmentMarket Watch • 10/20/20
Aptinyx Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress DisorderBusiness Wire • 10/19/20
Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with FibromyalgiaBusiness Wire • 09/28/20
5 Red-Hot Biotech and Medtech Stocks Under $10 With Massive Upside Potential24/7 Wall Street • 08/15/20
Aptinyx Inc (APTX) CEO Norbert Riedel on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/14/20
Aptinyx to Report Second Quarter Financial Results on Thursday, August 13, 2020Business Wire • 07/30/20
Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress DisorderGlobeNewsWire • 06/18/20
Aptinyx Inc. (APTX) Moves to Strong Buy: Rationale Behind the UpgradeZacks Investment Research • 05/20/20
Aptinyx Inc. (APTX) CEO Norbert Riedel on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/15/20